The association of socioeconomic status with receipt of neoadjuvant chemotherapy

Joan M. Neuner, Amanda Kong, Anne H Blaes, Danielle Riley, Elizabeth Chrischilles, Alicia Smallwood, Ingrid Lizarraga, Mary Schroeder

Research output: Contribution to journalArticle

Abstract

Background: There are advantages to neoadjuvant chemotherapy in operable breast cancer, particularly for those with higher-risk cancers, but little is known about factors that are associated with the use of neoadjuvant chemotherapy outside of clinical trials. We examined whether use of neoadjuvant chemotherapy instead of adjuvant chemotherapy varies by nonclinical factors such as patient socioeconomic status or rural residence. Methods: Women diagnosed with breast cancer in 2013–2014 at eight medical institutions were surveyed by mail regarding their experiences with breast cancer treatment, and this information was linked to hospital-based cancer registries. We examined the use of neoadjuvant chemotherapy among women with histologically confirmed invasive stage I–III breast cancer and used regression models to examine the association of socioeconomic status with chemotherapy timing. We also explored potential mechanisms for those differences. Results: Over 29% of the chemotherapy sample overall received neoadjuvant chemotherapy. Neoadjuvant receipt was lower for those with income < $100,000 (AOR 0.56, 95% CI 0.2–0.9) even with adjustment for other demographics, stage, and biomarker status, and findings for education and a variable for both lowest education and income < $100,000 were similar. Rural/urban residence was not associated with neoadjuvant receipt. Differences by income in perceptions of the importance of neoadjuvant chemotherapy advantages and disadvantages did not appear to explain the differences in use by income. Conclusions: In a multicenter sample of breast cancer patients, lower income was strongly associated with less receipt of neoadjuvant chemotherapy. Since patients with lower socioeconomic status are more likely to present with later-stage disease, this pattern has the potential to contribute to breast cancer outcome disparities.

Original languageEnglish (US)
Pages (from-to)179-188
Number of pages10
JournalBreast Cancer Research and Treatment
Volume173
Issue number1
DOIs
StatePublished - Jan 15 2019

Fingerprint

Social Class
Drug Therapy
Breast Neoplasms
Education
Cancer Care Facilities
Postal Service
Adjuvant Chemotherapy
Registries
Biomarkers
Demography
Clinical Trials
Neoplasms

Keywords

  • Breast cancer
  • Disparities
  • Neoadjuvant chemotherapy
  • Socioeconomic status

PubMed: MeSH publication types

  • Journal Article
  • Multicenter Study

Cite this

Neuner, J. M., Kong, A., Blaes, A. H., Riley, D., Chrischilles, E., Smallwood, A., ... Schroeder, M. (2019). The association of socioeconomic status with receipt of neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 173(1), 179-188. https://doi.org/10.1007/s10549-018-4954-0

The association of socioeconomic status with receipt of neoadjuvant chemotherapy. / Neuner, Joan M.; Kong, Amanda; Blaes, Anne H; Riley, Danielle; Chrischilles, Elizabeth; Smallwood, Alicia; Lizarraga, Ingrid; Schroeder, Mary.

In: Breast Cancer Research and Treatment, Vol. 173, No. 1, 15.01.2019, p. 179-188.

Research output: Contribution to journalArticle

Neuner, JM, Kong, A, Blaes, AH, Riley, D, Chrischilles, E, Smallwood, A, Lizarraga, I & Schroeder, M 2019, 'The association of socioeconomic status with receipt of neoadjuvant chemotherapy', Breast Cancer Research and Treatment, vol. 173, no. 1, pp. 179-188. https://doi.org/10.1007/s10549-018-4954-0
Neuner, Joan M. ; Kong, Amanda ; Blaes, Anne H ; Riley, Danielle ; Chrischilles, Elizabeth ; Smallwood, Alicia ; Lizarraga, Ingrid ; Schroeder, Mary. / The association of socioeconomic status with receipt of neoadjuvant chemotherapy. In: Breast Cancer Research and Treatment. 2019 ; Vol. 173, No. 1. pp. 179-188.
@article{65944d7017a54563bef0963bf955e196,
title = "The association of socioeconomic status with receipt of neoadjuvant chemotherapy",
abstract = "Background: There are advantages to neoadjuvant chemotherapy in operable breast cancer, particularly for those with higher-risk cancers, but little is known about factors that are associated with the use of neoadjuvant chemotherapy outside of clinical trials. We examined whether use of neoadjuvant chemotherapy instead of adjuvant chemotherapy varies by nonclinical factors such as patient socioeconomic status or rural residence. Methods: Women diagnosed with breast cancer in 2013–2014 at eight medical institutions were surveyed by mail regarding their experiences with breast cancer treatment, and this information was linked to hospital-based cancer registries. We examined the use of neoadjuvant chemotherapy among women with histologically confirmed invasive stage I–III breast cancer and used regression models to examine the association of socioeconomic status with chemotherapy timing. We also explored potential mechanisms for those differences. Results: Over 29{\%} of the chemotherapy sample overall received neoadjuvant chemotherapy. Neoadjuvant receipt was lower for those with income < $100,000 (AOR 0.56, 95{\%} CI 0.2–0.9) even with adjustment for other demographics, stage, and biomarker status, and findings for education and a variable for both lowest education and income < $100,000 were similar. Rural/urban residence was not associated with neoadjuvant receipt. Differences by income in perceptions of the importance of neoadjuvant chemotherapy advantages and disadvantages did not appear to explain the differences in use by income. Conclusions: In a multicenter sample of breast cancer patients, lower income was strongly associated with less receipt of neoadjuvant chemotherapy. Since patients with lower socioeconomic status are more likely to present with later-stage disease, this pattern has the potential to contribute to breast cancer outcome disparities.",
keywords = "Breast cancer, Disparities, Neoadjuvant chemotherapy, Socioeconomic status",
author = "Neuner, {Joan M.} and Amanda Kong and Blaes, {Anne H} and Danielle Riley and Elizabeth Chrischilles and Alicia Smallwood and Ingrid Lizarraga and Mary Schroeder",
year = "2019",
month = "1",
day = "15",
doi = "10.1007/s10549-018-4954-0",
language = "English (US)",
volume = "173",
pages = "179--188",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - The association of socioeconomic status with receipt of neoadjuvant chemotherapy

AU - Neuner, Joan M.

AU - Kong, Amanda

AU - Blaes, Anne H

AU - Riley, Danielle

AU - Chrischilles, Elizabeth

AU - Smallwood, Alicia

AU - Lizarraga, Ingrid

AU - Schroeder, Mary

PY - 2019/1/15

Y1 - 2019/1/15

N2 - Background: There are advantages to neoadjuvant chemotherapy in operable breast cancer, particularly for those with higher-risk cancers, but little is known about factors that are associated with the use of neoadjuvant chemotherapy outside of clinical trials. We examined whether use of neoadjuvant chemotherapy instead of adjuvant chemotherapy varies by nonclinical factors such as patient socioeconomic status or rural residence. Methods: Women diagnosed with breast cancer in 2013–2014 at eight medical institutions were surveyed by mail regarding their experiences with breast cancer treatment, and this information was linked to hospital-based cancer registries. We examined the use of neoadjuvant chemotherapy among women with histologically confirmed invasive stage I–III breast cancer and used regression models to examine the association of socioeconomic status with chemotherapy timing. We also explored potential mechanisms for those differences. Results: Over 29% of the chemotherapy sample overall received neoadjuvant chemotherapy. Neoadjuvant receipt was lower for those with income < $100,000 (AOR 0.56, 95% CI 0.2–0.9) even with adjustment for other demographics, stage, and biomarker status, and findings for education and a variable for both lowest education and income < $100,000 were similar. Rural/urban residence was not associated with neoadjuvant receipt. Differences by income in perceptions of the importance of neoadjuvant chemotherapy advantages and disadvantages did not appear to explain the differences in use by income. Conclusions: In a multicenter sample of breast cancer patients, lower income was strongly associated with less receipt of neoadjuvant chemotherapy. Since patients with lower socioeconomic status are more likely to present with later-stage disease, this pattern has the potential to contribute to breast cancer outcome disparities.

AB - Background: There are advantages to neoadjuvant chemotherapy in operable breast cancer, particularly for those with higher-risk cancers, but little is known about factors that are associated with the use of neoadjuvant chemotherapy outside of clinical trials. We examined whether use of neoadjuvant chemotherapy instead of adjuvant chemotherapy varies by nonclinical factors such as patient socioeconomic status or rural residence. Methods: Women diagnosed with breast cancer in 2013–2014 at eight medical institutions were surveyed by mail regarding their experiences with breast cancer treatment, and this information was linked to hospital-based cancer registries. We examined the use of neoadjuvant chemotherapy among women with histologically confirmed invasive stage I–III breast cancer and used regression models to examine the association of socioeconomic status with chemotherapy timing. We also explored potential mechanisms for those differences. Results: Over 29% of the chemotherapy sample overall received neoadjuvant chemotherapy. Neoadjuvant receipt was lower for those with income < $100,000 (AOR 0.56, 95% CI 0.2–0.9) even with adjustment for other demographics, stage, and biomarker status, and findings for education and a variable for both lowest education and income < $100,000 were similar. Rural/urban residence was not associated with neoadjuvant receipt. Differences by income in perceptions of the importance of neoadjuvant chemotherapy advantages and disadvantages did not appear to explain the differences in use by income. Conclusions: In a multicenter sample of breast cancer patients, lower income was strongly associated with less receipt of neoadjuvant chemotherapy. Since patients with lower socioeconomic status are more likely to present with later-stage disease, this pattern has the potential to contribute to breast cancer outcome disparities.

KW - Breast cancer

KW - Disparities

KW - Neoadjuvant chemotherapy

KW - Socioeconomic status

UR - http://www.scopus.com/inward/record.url?scp=85053679946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053679946&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4954-0

DO - 10.1007/s10549-018-4954-0

M3 - Article

VL - 173

SP - 179

EP - 188

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -